Brainomix Secures £14 Million for Healthcare Innovation Expansion
In the fast-evolving world of healthcare innovation, where AI is leading transformative change, Brainomix has emerged as a trailblazer. This Oxford-based company, known for its advanced imaging tools for stroke and lung fibrosis, recently secured an impressive £14 million in Series C funding. With a strategy focused on precision medicine, Brainomix is poised to revolutionize treatment decisions, catching the keen interest of investors eager to be part of this transformative journey.
Led by CEO Dr.
Michalis Papadakis, Brainomix is gaining significant momentum with its latest funding round co-led by Parkwalk Advisors and the Boehringer Ingelheim Venture Fund (BIVF). The excitement doesn’t stop there; new investor Hostplus, through the IP Group Hostplus Innovation Fund, has also joined this promising venture. This capital influx is strategically aimed at accelerating Brainomix's commercial expansion into the United States, especially following the company’s recent achievement of ten FDA clearances. This funding represents more than just capital; it embodies the trust and belief of investors in the potential of Brainomix’s solutions to make a notable impact in healthcare.
As a proud spinout from the University of Oxford, Brainomix is now establishing its footprint in a rapidly growing commercial landscape with offices in the UK, Ireland, and the USA. Operating in over 20 countries, the company is not just about technology; it’s about creating real-world impact. Their ongoing partnership with Boehringer Ingelheim focuses on enhancing the identification and access to treatments for individuals with progressive lung fibrosis. For startup founders and investors, Brainomix represents a compelling case study of innovation, strategic funding, and the drive to improve patient outcomes in critical areas of healthcare.
Key Terms Explained
- Series C funding
- This is a fundraising event typically aimed at developing a successful business as it gains significant momentum, expands new markets, acquires other businesses, or increases its customer base. It's usually the third round of venture capital funding for a successful startup.
- Precision medicine
- An emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle for each person. This approach allows doctors to select treatments that are most likely to help patients based on a genetic understanding of their disease.
- FDA clearance
- An official approval issued by the United States Food and Drug Administration (FDA) permitting the marketing and commercial deployment of a medical device or product within the United States. This is a pivotal milestone for healthcare startups intending to operate in the US market.
Frequently Asked Questions
- Who led the latest funding round for Brainomix?-The latest funding round for Brainomix was co-led by Parkwalk Advisors and the Boehringer Ingelheim Venture Fund (BIVF).
- How much funding did Brainomix secure in its Series C round?+
- What is the strategic aim of the capital influx into Brainomix?+
- What makes Brainomix attractive to investors?+
- What is the significance of Brainomix's partnership with Boehringer Ingelheim?+
They've invested in Brainomix
Get to know these Healthtech investors
| Investors | Investment Focus | Startup Investments | Round Size | Connect |
|---|---|---|---|---|
 Boehringer Ingelheim Venture Fund (BIVF)( ) | ||||
 Hostplus( ) | ||||
| All investors | All investor sectors | All funded startups | All funding rounds |
Click here for a full list of 7,589+ startup investors in the UK